By The Associated Press
Federal regulators say approval of the first generic version of cancer drug Doxil will help resolve a lingering shortage triggered by manufacturing deficiencies.
The shortage of the Johnson & Johnson injectable medication, made under contract by Ben Venue Laboratories, has continued on and off for a few years. It's resulted in rationing, with some patients with ovarian and other cancers getting less-effective care, and disrupted studies testing Doxil against possible new treatments.
The Food and Drug Administration says it's approved a generic version, called doxorubicin, made by Sun Pharma Global FZE. Last February, the FDA authorized temporary importation from India of a brand-name version, called Lipodox, also made by Sun Pharma. It's a subsidiary of an Indian drugmaker.
Meanwhile, J&J continues to seek a contract manufacturer to replace Ben Venue.
Related stories:
Hospitals scramble to get scarce kids' cancer drugs
Amid shortages, rules force hospitals to trash scarce drugs
Patients cheer as FDA eases shortage of two critical cancer meds
? 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Source: http://vitals.nbcnews.com/_news/2013/02/04/16842370-fda-allows-generic-of-scarce-cancer-drug?lite
earth day activities mel gibson splunk dark shadows iau msft etan patz
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.